Phage therapy, the use of bacteriophages to treat bacterial
infections, has a history dating back to the early 20th century. It is
regaining momentum as a promising weapon against the rising threat of
multidrug-resistant (MDR) bacteria. Antibiotic resistance is an escalating
global health crisis, posing a severe threat to the control of microbial
diseases. This comprehensive review
explores the historical context, the modern resurgence of phage therapy, and
phage-facilitated advancements in medical and technological fields. It details
the mechanisms of action and applications of phages in treating MDR bacterial
infections, particularly those associated with biofilms and intracellular
pathogens. The review further highlights innovative uses of phages in vaccine
development, cancer therapy, and as gene delivery vectors. Despite its targeted
and efficient approach, phage therapy faces challenges related to phage
stability, immune response, and regulatory approval. By examining these areas
in detail, this review underscores the immense potential and remaining hurdles
in integrating phage-based therapies into modern medical practices.
Author(s)
Details
Longzhu
Cui
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Shinya
Watanabe
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University,
Shimotsuke City 329-0498, Japan.
Kazuhiko
Miyanaga
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Kotaro
Kiga
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan
and Research Center for Drug and Vaccine Development, National Institute of
Infectious Diseases, Tokyo 162-8640, Japan.
Teppei
Sasahara
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Yoshifumi
Aiba
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Xin-Ee
Tan
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Srivani
Veeranarayanan
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Kanate
Thitiananpakorn
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Huong
Minh Nguyen
Division of Bacteriology, Department of Infection and Immunity,
School of Medicine, Jichi Medical University, Shimotsuke City 329-0498, Japan.
Dhammika
Leshan Wannigama
Department of Infectious Diseases and Infection Control, Yamagata
Prefectural Central Hospital, Yamagata 990-2292, Japan.
Please see the book here:- https://doi.org/10.9734/bpi/psnid/v7/4886
No comments:
Post a Comment